Reproducibility is a foundational element of the scientific method, a benchmark upon which the reliability of an experiment can be tested. However, the field is facing alarmingly high irreproducibility rates as illustrated in various industry publications, with reports ranging from 50% to 80% of published results not being reproducible. It has been estimated that in the US alone, $28B in funding is spent on preclinical research that is not reproducible. This estimation does not even take into account the impact on delaying translational research and causing high failure rates observed for the development of new treatments. To face this urgency head on, international consortia and collaborations between various stakeholders, including public-private partnerships, were formed to exchange, develop and implement quality standards and best practices. This session will examine these key findings.